



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/692,634	10/19/2000	Paul John Rennie	8308	8314

27752      7590      08/11/2006

THE PROCTER & GAMBLE COMPANY  
INTELLECTUAL PROPERTY DIVISION  
WINTON HILL BUSINESS CENTER - BOX 161  
6110 CENTER HILL AVENUE  
CINCINNATI, OH 45224

EXAMINER

WILLIAMS, LEONARD M

ART UNIT      PAPER NUMBER

1617

DATE MAILED: 08/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

<b>Application No.</b> 09/692,634	<b>Applicant(s)</b> RENNIE ET AL.	
<b>Examiner</b> Leonard M. Williams	<b>Art Unit</b> 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1)  Responsive to communication(s) filed on \_\_\_\_\_.
- 2a)  This action is **FINAL**.
- 2b)  This action is non-final.
- 3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4)  Claim(s) 1-7, 20-27 and 30-37 is/are pending in the application.  
4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5)  Claim(s) \_\_\_\_\_ is/are allowed.
- 6)  Claim(s) 1-7, 20-27 and 30-37 is/are rejected.
- 7)  Claim(s) \_\_\_\_\_ is/are objected to.
- 8)  Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9)  The specification is objected to by the Examiner.
- 10)  The drawing(s) filed on \_\_\_\_\_ is/are: a)  accepted or b)  objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11)  The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a)  All b)  Some \* c)  None of:  
1.  Certified copies of the priority documents have been received.  
2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1)  Notice of References Cited (PTO-892)
- 2)  Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3)  Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4)  Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_
- 5)  Notice of Informal Patent Application (PTO-152)
- 6)  Other: \_\_\_\_\_

Detailed Action

***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 4/10/2006 has been entered.

***Response to Amendment/Arguments***

The amendment filed 4/10/2006 amending claims 1-2 and 20; adding new claims 31-37; and canceling claims 8-19 and 28-30 has been entered.

All rejections from the previous office action are withdrawn.

Applicant's arguments with respect to claims 1-7, 20-27 and 31-37 have been considered but are moot in view of the new ground(s) of rejection.

***Specification***

The disclosure is objected to because of the following informalities: On page 5 lines 17-34 the applicants seem to indicate that the D, L and DL stereoisomers of pyroglutamic acid are also known as D, L and DL-Proline. This is incorrect as

Art Unit: 1617

pyroglutamic acid and proline are different compounds with different chemical structures, activities and status in the art. The stating that pyroglutamic acid and proline are interchangeable names is repugnant to one of the art. The insertion of a comma or semi-colon after the 5-oxo of "D-proline, 5-oxo" may correct this.

Appropriate correction is required.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was

Art Unit: 1617

not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-7, 20-27 and 30-37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Deihl (EP0505374B1), in view of Makino et al. (US Patent No. 4789667) and further in view of Kuhrt et al. (Virucidal Activity of Glutaric Acid and Evidence for Dual Mechanism of Action, Antimicrobial Agents and Chemotherapy, Dec. 1984, pp. 924-927).

Deihl teaches, on page 2, a pharmacological composition for treatment of the common cold by spraying said composition into the oral cavity (with mucosal absorption of the composition posited as the means of administration). The composition comprises vitamin C (ascorbic acid) and a non-toxic zinc salt. In example I Table 1 Deihl teaches a suitable zinc-vitamin C composition that includes pharmaceutical grade water, ascorbic acid (1.64% by weight), sodium bicarbonate (0.14% by weight), glycerine, potassium sorbate, EDTA, zinc gluconate (1.09% by weight), L-lysine, glycine, fruit juice, sucrose, magnasweet, tween-80, trace bioflavonoids, orange flavoring and peppermint oil.

Deihl does not teach direct spraying of the composition into the nasal turbinates, or the use of pyroglutamic acid in the composition.

Makino et al. teach, in the abstract, a pharmaceutical composition for external use with enhanced penetration of a pharmacologically active agent through the skin or

Art Unit: 1617

mucosa, said composition comprising a pharmacologically active agent and an optically active or inactive pyroglutamic acid ester.

In col. 3 lines 55-65, Makino et al. teach that in US Patent No. 4434159 a drug which is substantially unabsorbable through the mucosa of the rectum is made absorbable through the rectal mucosa by co-administration with a penetration enhancer (pyroglutamic acid or a salt thereof).

Makino et al. teach, in col. 12 lines 17-40, that the compositions contain the penetration enhancer in an amount of from 0.2-25% by weight, preferably 0.5-12% by weight based on the total weight of the composition. Further the mucosa may be that of the rectum, oral cavity, nasal cavity or vagina.

Makino et al. teach, in col. 14 line 1 to col. 15 (table 2 comparison 16 and 17), ointments prepared from 1 part of nifedipine, 10 parts L-pyroglutamic acid (comparison 1) or 10 parts DL-pyroglutamic acid (comparison 2), 89 parts of a gel ointment base (composed of 1 part of Carbopol 934-a mucoadhesive agent as defined in the current specification page 8 lines 1-10, 12 parts of propylene glycol, 30 parts ethanol, 1 part diisopropanolamine and 56 parts water). Thus the penetration enhancer (L-pyroglutamic acid or DL-pyroglutamic acid) is present in 10% by weight, the Carbopol 934 is present in 1% by weight, and the pharmacologically active agent is present in 1% by weight.

Kuhr et al. teach, in the abstract, that Rhinoviruses as a group are notably sensitive to inactivation in solutions with a pH of less than 5.3. On page 924, Kuhr et

Art Unit: 1617

al. teach that glutaric acid (one of the organic acids currently claimed) has been demonstrated as an effective virucidal agent against rhinovirus on human skin.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the ointment composition of Makino et al. comprising a penetration enhancer (pyroglutamic acid) and ointment base (that could be applied to mucosa of the rectum, oral cavity, nasal cavity or vagina), with the pharmacological composition of Deihl comprising ascorbic acid and zinc gluconate in order to formulate a composition for treatment of the common cold. One would be motivated to add the Makino et al. ointment compositions to the Deihl compositions in order to achieve enhanced penetration of the ascorbic acid and zinc gluconate and thus achieve a greater effectiveness against the common cold. One would be motivated to adjust the overall pH of the combined formulation to less than pH 5.3 as Kuhrt et al. has demonstrated that rhinoviruses are inactivated by acidic conditions wherein the overall pH is less than 5.3. One would further be motivated to use glutaric acid as an organic acid with the combined formulation either in conjunction with ascorbic acid or by itself in treating the common cold as Kuhrt et al. show that Glutaric acid is an effective virucide against rhinovirus (on human skin).

The examiner respectfully points out the following from MPEP 2144.06:

"It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from

Art Unit: 1617

their having been individually taught in the prior art." *In re Kerkhoven*, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980).

The determination of optimal viscosity, optimal pH ranges, and optimal pKa ranges are matters of routine experimentation.

The examiner respectfully points out the following from MPEP 2144.05: "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); see also *Peterson*, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); *In re Hoeschele*, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969); *Merck & Co. Inc. v. Biocraft Laboratories Inc.*, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); *In re Kulling*, 897 F.2d 1147, 14 USPQ2d 1056 (Fed. Cir. 1990); and *In re Geisler*, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997).

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leonard M. Williams whose telephone number is 571-272-0685. The examiner can normally be reached on MF 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone




Art Unit: 1617

number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LMW

  
SREENI PADMANABHAN  
SUPERVISORY PATENT EXAMINER